These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8167208)

  • 21. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis.
    Hierholzer J; Cordes M; Schelosky L; Richter W; Keske U; Venz S; Semmler W; Poewe W; Felix R
    J Nucl Med; 1994 Dec; 35(12):1921-7. PubMed ID: 7989970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease.
    Oertel WH; Tatsch K; Schwarz J; Kraft E; Trenkwalder C; Scherer J; Weinzierl M; Vogl T; Kirsch CM
    Ann Neurol; 1992 Dec; 32(6):743-8. PubMed ID: 1471864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine and depression--striatal dopamine D2 receptor SPECT before and after antidepressant therapy.
    Ebert D; Feistel H; Loew T; Pirner A
    Psychopharmacology (Berl); 1996 Jul; 126(1):91-4. PubMed ID: 8853222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Striatal dopamine receptor binding in epileptic psychoses.
    Ring HA; Trimble MR; Costa DC; Moriarty J; Verhoeff NP; Ell PJ
    Biol Psychiatry; 1994 Mar; 35(6):375-80. PubMed ID: 8018783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H
    Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy.
    Hertel A; Weppner M; Baas H; Schreiner M; Maul FD; Baum RP; Fischer PA; Hör G
    Nucl Med Commun; 1997 Sep; 18(9):811-22. PubMed ID: 9352546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine D2-receptor imaging with 123I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier?
    Verhoeff NP; Visser WH; Ferrari MD; Saxena PR; van Royen EA
    Cephalalgia; 1993 Oct; 13(5):325-9. PubMed ID: 8242725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression.
    Larisch R; Klimke A; Vosberg H; Löffler S; Gaebel W; Müller-Gärtner HW
    Neuroimage; 1997 May; 5(4 Pt 1):251-60. PubMed ID: 9345554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Visualization of extrastriatal dopamine D2 receptors in the human brain.
    Kessler RM; Mason NS; Votaw JR; De Paulis T; Clanton JA; Ansari MS; Schmidt DE; Manning RG; Bell RL
    Eur J Pharmacol; 1992 Nov; 223(1):105-7. PubMed ID: 1478255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo characterization of R(+)-FIDA2: a dopamine D2-like imaging agent.
    Vessotskie JM; Kung MP; Chumpradit S; Romaniello G; McElgin W; Frederick D; Malison RT; Kung HF
    J Nucl Med; 1995 Jul; 36(7):1282-8. PubMed ID: 7790957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
    van Royen E; Verhoeff NF; Speelman JD; Wolters EC; Kuiper MA; Janssen AG
    Arch Neurol; 1993 May; 50(5):513-6. PubMed ID: 8489409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Altered striatal dopamine D2 receptor density and dopamine transport in a patient with hepatic encephalopathy.
    Weissenborn K; Berding G; Köstler H
    Metab Brain Dis; 2000 Sep; 15(3):173-8. PubMed ID: 11206586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: preliminary results of a dynamic [123I] IBZM SPECT study.
    Pogarell O; Koch W; Pöpperl G; Tatsch K; Jakob F; Zwanzger P; Mulert C; Rupprecht R; Möller HJ; Hegerl U; Padberg F
    J Psychiatr Res; 2006 Jun; 40(4):307-14. PubMed ID: 16259998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
    Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
    J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.
    Schwarz J; Antonini A; Kraft E; Tatsch K; Vogl T; Kirsch CM; Leenders KL; Oertel WH
    Neurology; 1994 Jun; 44(6):1079-82. PubMed ID: 8208404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET.
    Gray NS; Pilowsky LS; Gray JA; Kerwin RW
    Schizophr Res; 1995 Sep; 17(1):95-107. PubMed ID: 8541255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine D2-receptors in human narcolepsy: a SPECT study with 123I-IBZM.
    Hublin C; Launes J; Nikkinen P; Partinen M
    Acta Neurol Scand; 1994 Sep; 90(3):186-9. PubMed ID: 7847059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
    Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
    Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study.
    Oliver DW; Dormehl IC; Van der Schyf CJ; Neumeyer JL; Hugo N; Keeve R; Rossouw NT; Müller-Gärtner HW; Castagnoli N
    Arzneimittelforschung; 1997 Jun; 47(6):692-9. PubMed ID: 9239444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.